By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

WuXi XDC Cayman Inc (2268.HK)

HKSE Currency in CNY
¥59.35
+¥2.75
+4.86%
Last Update: 1 Sept 2025, 05:26
¥71.49B
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
¥18.52 - ¥64.45
52 Week Range

2268.HK Stock Price Chart

Explore WuXi XDC Cayman Inc interactive price chart. Choose custom timeframes to analyze 2268.HK price movements and trends.

2268.HK Company Profile

Discover essential business fundamentals and corporate details for WuXi XDC Cayman Inc (2268.HK) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

IPO Date

18 Jun 2012

Employees

2.04K

CEO

Jincai Li

Description

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

2268.HK Financial Timeline

Browse a chronological timeline of WuXi XDC Cayman Inc corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 23 Mar 2026

Earnings released on 20 Aug 2025

Earnings released on 18 Aug 2025

EPS came in at ¥0.63 falling short of the estimated ¥0.67 by -6.44%, while revenue for the quarter reached ¥2.96B , beating expectations by +3.98%.

Earnings released on 24 Mar 2025

EPS came in at ¥0.52 surpassing the estimated ¥0.48 by +8.98%, while revenue for the quarter reached ¥2.54B , beating expectations by +14.15%.

Earnings released on 20 Aug 2024

EPS came in at ¥0.19 falling short of the estimated ¥0.25 by -23.19%, while revenue for the quarter reached ¥832.60M , missing expectations by -45.96%.

Earnings released on 30 Jun 2024

EPS came in at ¥0.19 , while revenue for the quarter reached ¥832.60M .

Earnings released on 31 Dec 2023

EPS came in at ¥0.05 falling short of the estimated ¥0.11 by -57.35%, while revenue for the quarter reached ¥565.19M , missing expectations by -40.81%.

Earnings released on 30 Sept 2023

EPS came in at ¥0.05 , while revenue for the quarter reached ¥565.19M .

Earnings released on 30 Jun 2023

EPS came in at ¥0.09 , while revenue for the quarter reached ¥505.88M .

Earnings released on 31 Mar 2023

EPS came in at ¥0.07 , while revenue for the quarter reached ¥487.59M .

Earnings released on 31 Dec 2022

EPS came in at ¥0.03 , while revenue for the quarter reached ¥330.49M .

Earnings released on 30 Jun 2022

EPS came in at ¥0.06 , while revenue for the quarter reached ¥208.01M .

Earnings released on 31 Mar 2022

EPS came in at ¥0.03 , while revenue for the quarter reached ¥121.43M .

2268.HK Stock Performance

Access detailed 2268.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run